基质金属蛋白酶2/9在慢性肝脏疾病发生发展中的作用

杨尚青; 杨东亮; 刘嘉

doi:10.3969/j.issn.1001-5256.2020.10.045

基质金属蛋白酶2/9在慢性肝脏疾病发生发展中的作用

DOI: 10.3969/j.issn.1001-5256.2020.10.045

华中科技大学同济医学院附属协和医院感染性疾病科

基金项目:

国家自然科学基金资助项目(81861138044,91642118,91742114)；国家科技重大专项资助项目(2017ZX10202202,2017ZX10202201,2017ZX10202203-007-006)；华中科技大学同济医学院重大疾病交叉创新团队资助项目；

详细信息

中图分类号: R575
计量
- 文章访问数: 536
- HTML全文浏览量: 11
- PDF下载量: 63
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-07
- 出版日期: 2020-10-20

Role of matrix metalloproteinases-2 and matrix metalloproteinases-9 in the development and progression of chronic liver diseases

Department of Infectious Diseases,Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Research funding:

摘要

摘要: 细胞外基质的降解和重塑是多种慢性肝脏疾病进展过程中的重要病理生理现象。近年来,随着对基质金属蛋白酶（MMP）研究的不断拓展,发现其不仅可影响细胞外基质的降解和重塑过程,还可通过多种机制参与炎症及免疫应答的发生和调控,进而参与肝脏疾病的进程。简述了MMP家族成员MMP-2/MMP-9的基本特性、表达活性调控机制及其在多种慢性肝脏疾病发生发展中的作用,旨在为探索慢性肝脏疾病新的治疗策略提供依据。
- 肝疾病 /
- 基质金属蛋白酶2 /
- 基质金属蛋白酶9 /
- 免疫
Abstract: The degradation and remodelling of extracellular matrix are important pathophysiological phenomena during the progression of various chronic liver diseases. With the expanded research on matrix metalloproteinases( MMPs) in recent years,it has been found that MMPs can affect the degradation and remodelling of extracellular matrix,participate in the regulation of inflammation and immune responses through various mechanisms,and thus participate in the progression of liver diseases. This article reviews the basic characteristics of matrix metalloproteinase-2 and matrix metalloproteinase-9,their regulatory mechanisms,and their role in the development and progression of chronic liver diseases,so as to provide a basis for exploring new therapeutic strategies for chronic liver diseases.
- liver diseases /
- matrix metalloproteinase 2 /
- matrix metalloproteinase 9 /
- immunity

HTML全文

参考文献(45)

[1] PATTEN DA,SHETTY S. Chronic liver disease:Scavenger hunt for novel therapies[J]. Lancet,2018,391(10116):104-105.

[2] ROEB E. Matrix metalloproteinases and liver fibrosis(translational aspects)[J]. Matrix Biol,2018,68-69:463-473.

[3] XU Y,ZHOU W,JI Y,et al. Elongator promotes the migration and invasion of hepatocellular carcinoma cell by the phosphorylation of AKT[J]. Int J Biol Sci,2018,14(5):518-530.

[4] DUARTE S,BABER J,FUJII T,et al. Matrix metalloproteinases in liver injury,repair and fibrosis[J]. Matrix Biol,2015,44-46:147-156.

[5] GROSS J,LAPIERE CM. Collagenolytic activity in amphibian tissues:A tissue culture assay[J]. Proc Natl Acad Sci U S A,1962,48:1014-1022.

[6] ADHIKARI N,MUKHERJEE A,SAHA A,et al. Arylsulfonamides and selectivity of matrix metalloproteinase-2:An overview[J]. Eur J Med Chem,2017,129:72-109.

[7] KLEIN T,BISCHOFF R. Physiology and pathophysiology of matrix metalloproteases[J]. Amino Acids,2011,41(2):271-290.

[8] ARISTORENA M,GALLARDO-VARA E,VICEN M,et al.MMP-12,secreted by pro-inflammatory macrophages,targets endoglin in human macrophages and endothelial cells[J]. Int J Mol Sci,2019,20(12):3107.

[9] TOUMPANAKIS D,NOUSSIA O,SIGALA I,et al. Inspiratory resistive breathing induces MMP-9 and MMP-12 expression in the lung[J]. Am J Physiol Lung Cell Mol Physiol,2015,308(7):1683-1692.

[10] CUI N,HU M,KHALIL RA. Biochemical and biological attributes of matrix metalloproteinases[J]. Prog Mol Biol Transl Sci,2017,147:1-73.

[11] ARPINO V,BROCK M,GILL SE. The role of TIMPs in regulation of extracellular matrix proteolysis[J]. Matrix Biol,2015,44-46:247-254.

[12] AMLINEI C,CRUNTU ID,GIU爦CSE,et al. Matrix metalloproteinases involvement in pathologic conditions[J]. Rom J Morphol Embryol,2010,51(2):215-228.

[13] van DOREN SR. Matrix metalloproteinase interactions with collagen and elastin[J]. Matrix Biol,2015,44-46:224-231.

[14] DANIELE A,ABBATE I,OAKLEY C,et al. Clinical and prognostic role of matrix metalloproteinase-2,-9 and their inhibitors in breast cancer and liver diseases:A review[J]. Int J Biochem Cell Biol,2016,77(Pt A):91-101.

[15] YANG Q,LI X. Corrigendum:Molecular network basis of invasive pituitary adenoma:A review[J]. Front Endocrinol(Lausanne),2019,10:657.

[16] JIN Y,CHEN W,YANG H,et al. Scutellaria barbata D. Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways[J]. Exp Ther Med,2017,14(6):5527-5534.

[17] JING SW,WANG YD,KURODA M,et al. HIF-1αcontributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression[J]. Acta Med Okayama,2012,66(5):399-407.

[18] KURZEPA J,M DRO A,CZECHOWSKA G,et al. Role of MMP-2 and MMP-9 and their natural inhibitors in liver fibrosis,chronic pancreatitis and non-specific inflammatory bowel diseases[J]. Hepatobiliary Pancreat Dis Int,2014,13(6):570-579.

[19] JACOB A,JING J,LEE J,et al. Rab40b regulates trafficking of MMP2 and MMP9 during invadopodia formation and invasion of breast cancer cells[J]. J Cell Sci,2013,126(Pt 20):4647-4658.

[20] CHENG Z,LIMBU MH,WANG Z,et al. MMP-2 and 9 in chronic kidney disease[J]. Int J Mol Sci,2017,18(4):776.

[21] DONG DD,ZHOU H,LI G. ADAM15 targets MMP9 activity to promote lung cancer cell invasion[J]. Oncol Rep,2015,34(5):2451-2460.

[22] TOTH M,CHVYRKOVA I,BERNARDO MM,et al. Pro-MMP-9activation by the MT1-MMP/MMP-2 axis and MMP-3:Role of TIMP-2 and plasma membranes[J]. Biochem Biophys Res Commun,2003,308(2):386-395.

[23] ALA-AHO R,KHRI VM. Collagenases in cancer[J]. Biochimie,2005,87(3-4):273-286.

[24] IIMURO Y,NISHIO T,MORIMOTO T,et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat[J]. Gastroenterology,2003,124(2):445-458.

[25] NU'EZ O,FERNNDEZ-MARTNEZ A,MAJANO PL,et al.Increased intrahepatic cyclooxygenase 2,matrix metalloproteinase 2,and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection:Role of viral core and NS5A proteins[J]. Gut,2004,53(11):1665-1672.

[26] HEMMANN S,GRAF J,RODERFELD M,et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies[J]. J Hepatol,2007,46(5):955-975.

[27] ZHOU X,HOVELL CJ,PAWLEY S,et al. Expression of matrix metalloproteinase-2 and-14 persists during early resolution of experimental liver fibrosis and might contribute to fibrolysis[J]. Liver Int,2004,24(5):492-501.

[28] GIANNANDREA M,PARKS WC. Diverse functions of matrix metalloproteinases during fibrosis[J]. Dis Model Mech,2014,7(2):193-203.

[29] WANG J,PAN W,WANG Y,et al. Enhanced efficacy of curcumin with phosphatidylserine-decorated nanoparticles in the treatment of hepatic fibrosis[J]. Drug Deliv,2018,25(1):1-11.

[30] MEIER RP,MAHOU R,MOREL P,et al. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice[J]. J Hepatol,2015,62(3):634-641.

[31] FENG M,DING J,WANG M,et al. Kupffer-derived matrix metalloproteinase-9 contributes to liver fibrosis resolution[J].Int J Biol Sci,2018,14(9):1033-1040.

[32] EL-GINDY I,EL RAHMAN AT,EL-ALIM MA,et al. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease[J]. Egypt J Immunol,2003,10(1):27-35.

[33] LU C,RONG D,ZHANG B,et al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma:Challenges and opportunities[J]. Mol Cancer,2019,18(1):130.

[34] LIN XL,LI K,YANG Z,et al. Dulcitol suppresses proliferation and migration of hepatocellular carcinoma via regulating SIRT1/p53 pathway[J]. Phytomedicine,2020,66:153112.

[35] HUANG CF,TENG YH,LU FJ,et al．β-mangostin suppresses human hepatocellular carcinoma cell invasion through inhibition of MMP-2 and MMP-9 expression and activating the ERK and JNK pathways[J]. Environ Toxicol,2017,32(11):2360-2370.

[36] YOSHIJI H,KURIYAMA S,NOGUCHI R,et al. Angiopoietin 2displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice[J]. Gut,2005,54(12):1768-1775.

[37] CAO LQ,SHAO ZL,LIANG HH,et al. Activation of peroxisome proliferator-activated receptor-γ(PPARγ)inhibits hepatoma cell growth via downregulation of SEPT2 expression[J]. Cancer Lett,2015,359(1):127-135.

[38] MONDAL S,ADHIKARI N,BANERJEE S,et al. Matrix metalloproteinase-9(MMP-9)and its inhibitors in cancer:A minireview[J]. Eur J Med Chem,2020,194:112260.

[39] LI JZ,LI J,LIU BZ. MicroRNA-328-3p inhibits malignant progression of hepatocellular carcinoma by regulating MMP-9 level[J]. Eur Rev Med Pharmacol Sci,2019,23(21):9331-9340.

[40] ZHANG Q,ZHANG Y,HU X,et al. Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma[J]. Lab Invest,2017,97(8):903-912.

[41] LI T,ZHONG J,DONG X,et al. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of theβ-catenin signaling pathway[J]. Oncol Rep,2016,35(6):3614-3622.

[42] DANIELE A,DIVELLA R,QUARANTA M,et al. Clinical and prognostic role of circulating MMP-2 and its inhibitor TIMP-2 in HCC patients prior to and after trans-hepatic arterial chemo-embolization[J]. Clin Biochem,2014,47(3):184-190.

[43] STARR AE,DUFOUR A,MAIER J,et al. Biochemical analysis of matrix metalloproteinase activation of chemokines CCL15and CCL23 and increased glycosaminoglycan binding of CCL16[J]. J Biol Chem,2012,287(8):5848-5860.

[44] KLEIFELD O,DOUCET A,AUF DEM KELLER U,et al. Isotopic labeling of terminal amines in complex samples identifies protein N-termini and protease cleavage products[J]. Nat Biotechnol,2010,28(3):281-288.

[45] YANG S,WANG L,PAN W,et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol,2019,71(4):685-698.

施引文献

资源附件(0)

访问统计